KR20190039974A - 비구아니드들로 발달 장애들을 치료하는 방법들 - Google Patents

비구아니드들로 발달 장애들을 치료하는 방법들 Download PDF

Info

Publication number
KR20190039974A
KR20190039974A KR1020197006647A KR20197006647A KR20190039974A KR 20190039974 A KR20190039974 A KR 20190039974A KR 1020197006647 A KR1020197006647 A KR 1020197006647A KR 20197006647 A KR20197006647 A KR 20197006647A KR 20190039974 A KR20190039974 A KR 20190039974A
Authority
KR
South Korea
Prior art keywords
syndrome
metformin
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197006647A
Other languages
English (en)
Korean (ko)
Inventor
메튜 듀링
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20190039974A publication Critical patent/KR20190039974A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197006647A 2016-08-18 2017-08-18 비구아니드들로 발달 장애들을 치료하는 방법들 Ceased KR20190039974A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
US62/376,488 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (1)

Publication Number Publication Date
KR20190039974A true KR20190039974A (ko) 2019-04-16

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197006647A Ceased KR20190039974A (ko) 2016-08-18 2017-08-18 비구아니드들로 발달 장애들을 치료하는 방법들

Country Status (9)

Country Link
US (2) US10123979B2 (https=)
EP (1) EP3484452A4 (https=)
JP (1) JP2019524834A (https=)
KR (1) KR20190039974A (https=)
CN (1) CN109715144A (https=)
AU (1) AU2017313823A1 (https=)
CA (1) CA3033967A1 (https=)
MX (1) MX2019001937A (https=)
WO (1) WO2018035408A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
CN109715144A (zh) 2016-08-18 2019-05-03 奥维德医疗公司 使用双胍类治疗发育障碍的方法
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) * 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
CN113318111B (zh) * 2021-06-21 2026-02-03 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
EP4440560A1 (en) * 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP2005537298A (ja) * 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CN102058888B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
US20140256820A1 (en) * 2010-12-13 2014-09-11 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
WO2014210389A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
CN109715144A (zh) 2016-08-18 2019-05-03 奥维德医疗公司 使用双胍类治疗发育障碍的方法

Also Published As

Publication number Publication date
MX2019001937A (es) 2019-10-02
CA3033967A1 (en) 2018-02-22
WO2018035408A1 (en) 2018-02-22
US20180050001A1 (en) 2018-02-22
US10426746B2 (en) 2019-10-01
US20190046480A1 (en) 2019-02-14
JP2019524834A (ja) 2019-09-05
EP3484452A4 (en) 2020-04-01
CN109715144A (zh) 2019-05-03
US10123979B2 (en) 2018-11-13
EP3484452A1 (en) 2019-05-22
AU2017313823A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US12465597B2 (en) Methods of treating developmental disorders with gaboxadol
KR20190039974A (ko) 비구아니드들로 발달 장애들을 치료하는 방법들
KR20190086709A (ko) 가복사돌로 주의력 결핍/과잉행동 장애를 치료하는 방법들
HK40097170A (zh) 用加波沙朵治疗发育障碍的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200731

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210929

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220325

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I